Although the G551D mutation is only present in 5% of the CF population, the success of ivacaftor showed that modulators are effective in rescuing CFTR protein function, opening the door for the discovery of additional novel modulators that may be relevant to a broader population of CF patients. Here, CFTR is linked to cystic fibrosis.